Letters to the Editor
Case Report: Risk of Uterine Perforation from IUDs Is Greatest During Postpartum Period
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2013 Nov 15;88(10):634-636.
TO THE EDITOR: Uterine perforation is a rare but potentially serious complication of the levonorgestrel-releasing intrauterine device (IUD; Mirena); the incidence is estimated at 0 to 2.6 per 1,000 insertions.1 Perforation typically occurs during IUD insertion, and symptoms can include abdominal pain and uterine bleeding. However, perforation can go unrecognized for months or years if asymptomatic.1–3
When recognized, an IUD that has perforated the uterus should be removed promptly because bowel perforation, obstruction, or adhesions can occur.1,2 Also, a malpositioned IUD may not prevent an unintended pregnancy.1–5 Although the levonorgestrel-releasing IUD can be inserted in a nonpregnant woman at any time, including immediately postpartum, the risk of perforation is greatest during the 12 weeks after giving birth and while the patient is lactating.1,4–6
We present the following case:
A 31-year-old woman (two pregnancies, one full-term delivery, one miscarriage, one living child) presented to a family medicine clinic 12 months after insertion of a levonorgestrel-releasing IUD with frequent, irregular, and increasingly heavy menstrual bleeding. She requested that the IUD be removed. It had been placed six weeks postpartum, and the patient was breastfeeding. Attempts to remove the IUD in the clinic were unsuccessful, and the use of abdominal and pelvic ultrasonography failed to locate it. Abdominal radiography revealed that the IUD was located in the right lateral pelvis (Figure 1). Although it was loosely tangled in the right fimbria, it was successfully removed using laparoscopy. No uterine structural abnormalities were found.
Clinicians and patients should carefully weigh the benefits and risks of IUD insertion during the postpartum period. A follow-up examination four to 12 weeks after insertion is recommended to ensure correct positioning; patients may opt to use another effective family planning method until this examination has occurred.
Author disclosure: No relevant financial affiliations.
1. Van Houdenhoven K, van Kaam KJ, van Grootheest AC, Salemans TH, Dunselman GA. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception. 2006;73(3):257–260.
2. Gill RS, Mok D, Hudson M, Shi X, Birch DW, Karmali S. Laparoscopic removal of an intra-abdominal intrauterine device: case and systematic review. Contraception. 2012;85(1):15–18.
3. Andersson K, Ryde-Blomqvist E, Lindell K, Odlind V, Milsom I. Perforations with intrauterine devices. Report from a Swedish survey. Contraception. 1998;57(4):251–255.
4. Mirena (levonorgestrel-releasing intrauterine system) [package insert]. Wayne, N.J.: Bayer HealthCare; 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021225s019lbl.pdf. Accessed August 26, 2013.
5. Turok DK, Gurtcheff SE, Gibson K, Handley E, Simonsen S, Murphy PA. Operative management of intrauterine device complications: a case series report. Contraception. 2010;82(4):354–357.
6. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep. 2013;62(RR-05):1–60.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2013 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions